Physician profile
Mohammad Baddad
NPI 1598110058
$2,532.34
in general payments reported to CMS, 2019-2025
20 companies · $300 in 2025
The $300 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $148 · 2021: $684 · 2022: $1,385 · 2023: $15.13 · 2025: $300.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $300 · Food and Beverage: $15.13.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $300.00 |
| Food and Beverage | $15.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $679.01 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $274.31 | 2022 | |
| Biogen, INC. | $273.01 | 2021-2025 | Tysabri |
| Jazz Pharmaceuticals INC. | $150.00 | 2025 | |
| Merz Pharmaceuticals, LLC | $147.38 | 2021-2022 | |
| Sk Life Science, INC. | $147.27 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $87.95 | 2022-2023 | Austedo Xr |
| Genzyme Corporation | $86.08 | 2022 | |
| Allergan, INC. | $77.62 | 2021-2022 | |
| Argenx US, INC. | $67.45 | 2022 | |
| Currax Pharmaceuticals LLC | $59.26 | 2021-2022 | |
| Medtronic, INC. | $58.65 | 2022 | |
| Neurelis, INC. | $54.03 | 2021 | |
| Amneal Pharmaceuticals LLC | $53.68 | 2022 | |
| Lilly USA, LLC | $45.44 | 2022 |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceuticals, INC. | $39.82 | 2021 | |
| Scilex Pharmaceuticals INC. | $21.77 | 2022 | |
| Neurocrine Biosciences, INC. | $21.49 | 2021 | |
| Boston Scientific Corporation | $19.99 | 2021 | |
| Lundbeck LLC | $19.97 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohammad Baddad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.